CT45-1 activators encompass a range of chemical compounds that indirectly augment the functionality of CT45-1, primarily through pathways related to antigen presentation. Bestatin, as a protease inhibitor, enhances CT45-1's role by increasing peptide availability for MHC class I molecules, a key component of the antigen presentation pathway in which CT45-1 is involved. Similarly, MG-132 and Lactacystin, both proteasome inhibitors, contribute to the pool of peptides available for MHC class I presentation, indirectly enhancing CT45-1 activity. Disulfiram, by inhibiting the proteasome, leads to an accumulation of cytosolic proteins, thus providing a broader substrate range for antigen presentation. Leupeptin, another protease inhibitor, aligns with this mechanism, furthering the availability of antigenic peptides. Zinc Sulfate, through its role in maintaining the structural integrity of MHC class I molecules, and Calreticulin, as a calcium-binding chaperone involved in MHC class I molecule folding, also support CT45-1's function in antigen presentation. Additionally, Tunicamycin's impact on the maturation of MHC class I molecules indirectly influences CT45-1's role in this critical immune process.
In parallel, Sodium Butyrate and IFN-gamma enhance CT45-1's activity by modulating gene expression and upregulating components of the antigen presentation pathway, respectively. Sodium Butyrate, as a histone deacetylase inhibitor, facilitates chromatin remodeling, thereby enhancing the transcription of genes crucial in antigen presentation. IFN-gamma specifically upregulates MHC class I molecules, bolstering CT45-1's efficiency in this pathway. Brefeldin A and Chloroquine introduce alterations in antigen processing; Brefeldin A disrupts the Golgi apparatus, affecting MHC class I transport, while Chloroquine, by altering endosomal pH, impacts antigen processing for MHC class I presentation. These diverse mechanisms collectively enhance the functional activity of CT45-1 in the antigen presentation pathway, demonstrating the intricate interplay of biochemical and cellular processes in modulating protein function.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bestatin | 58970-76-6 | sc-202975 | 10 mg | $131.00 | 19 | |
Bestatin, a protease inhibitor, indirectly enhances CT45-1 activity by inhibiting aminopeptidases, leading to increased peptide presentation on MHC class I molecules, a process in which CT45-1 is involved. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Zinc Sulfate, by contributing to the structural integrity of the MHC class I molecule, can enhance CT45-1's role in antigen presentation. Zinc ions are crucial for the stabilization of MHC class I-peptide complexes. | ||||||
Sodium Butyrate | 156-54-7 | sc-202341 sc-202341B sc-202341A sc-202341C | 250 mg 5 g 25 g 500 g | $31.00 $47.00 $84.00 $222.00 | 19 | |
Sodium Butyrate acts as a histone deacetylase inhibitor, leading to chromatin remodeling. This enhances the transcription of genes involved in antigen presentation, indirectly supporting CT45-1's function. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132, a proteasome inhibitor, can enhance CT45-1's role by altering the degradation of proteins, leading to an increased pool of peptides available for MHC class I presentation. | ||||||
Disulfiram | 97-77-8 | sc-205654 sc-205654A | 50 g 100 g | $53.00 $89.00 | 7 | |
Disulfiram can indirectly enhance CT45-1 activity by inhibiting the proteasome, leading to an accumulation of cytosolic proteins, thus providing more substrates for antigen presentation in which CT45-1 is involved. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the Golgi apparatus, affecting the transport of MHC class I molecules. This can lead to an altered antigen presentation pathway, indirectly influencing CT45-1 activity. | ||||||
Leupeptin hemisulfate | 103476-89-7 | sc-295358 sc-295358A sc-295358D sc-295358E sc-295358B sc-295358C | 5 mg 25 mg 50 mg 100 mg 500 mg 10 mg | $73.00 $148.00 $316.00 $499.00 $1427.00 $101.00 | 19 | |
Leupeptin, a protease inhibitor, can increase the availability of peptides for MHC class I presentation, indirectly enhancing CT45-1's role in this process. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Lactacystin, another proteasome inhibitor, indirectly enhances CT45-1 activity by increasing the pool of peptides available for MHC class I presentation. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $69.00 | 2 | |
Chloroquine, by raising endosomal pH, can affect the processing of antigens for MHC class I presentation, indirectly influencing CT45-1 activity. | ||||||